Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

5.600 -0.030 (-0.53%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
3 High-Flying Stocks Facing Headwinds
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
Topics Malware
3 Stocks Under $10 in the Doghouse
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics Shares New Clinical Data Demonstrating Sensitivity of Precise MRD Across Multiple Cancer Types
MONSTAR-SCREEN-3 study showed 100% detection of circulating tumor DNA (ctDNA) at baseline timepoint, and 60% of patients testing positive one month after surgery had tumor fractions only detectable via... 
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Cash-Burning Stocks Facing Headwinds
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable. 
Via StockStory
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators 
From Myriad Genetics, Inc.
Via GlobeNewswire
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Small-Cap Stocks with Questionable Fundamentals
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
This UnitedHealth Group Analyst Turns Bearish; Here Are Top 3 Downgrades For Wednesday
Via Benzinga
CI&T, Novavax, Paramount Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year... 
Via StockStory
Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Correction: Time of BofA Conference 
From Myriad Genetics, Inc.
Via GlobeNewswire
3 of Wall Street’s Favorite Stocks in Dangerous Territory
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Myriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Myriad Genetics Shares Tank 41% On Analyst Downgrades, Weaker Guidance: Yet Retail Investors Remain Bullish
Analysts, including those from Wells Fargo, UBS, Raymond James, and Craig-Hallum, slashed their price targets and expressed concerns over the company's growth and execution challenges. 
Via Stocktwits
Securities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
What Analysts Are Saying About Myriad Genetics Stock
Via Benzinga
Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology
Study suggests that utilizing RiskScore drives breast cancer screening tailored to individual risk 
From Myriad Genetics, Inc.
Via GlobeNewswire
Top movers in Wednesday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS, and... 
Via StockStory
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Falls 1%; Uber Sales Miss Estimates
Via Benzinga
Topics Earnings
Wednesday's session: top gainers and losers
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday.
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Myriad Genetics (NASDAQ:MYGN) Misses Q1 Sales Targets, Stock Drops 14.5%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue... 
Via StockStory
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Which stocks are moving after the closing bell on Tuesday?
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.